Tg Therapeutics (TGTX) Payables (2010 - 2026)

Tg Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $148.8 million for Q1 2026.

• In Q1 2026, Payables rose 429.7% year-over-year to $148.8 million; the TTM figure through Mar 2026 stood at $148.8 million (up 429.7% YoY), while the FY2025 annual figure was $107.5 million, up 84.42% from the prior year.
• Payables was $148.8 million for Q1 2026 at Tg Therapeutics, up from $107.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $148.8 million in Q1 2026 to a low of $28.1 million in Q1 2025.
• Historically, Payables has averaged $72.2 million across 5 years, with a median of $58.3 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Payables tumbled 67.8% in 2025, then soared 429.7% in 2026.
• A 5-year view of Payables shows it stood at $42.0 million in 2022, then decreased by 8.44% to $38.5 million in 2023, then surged by 51.53% to $58.3 million in 2024, then surged by 84.42% to $107.5 million in 2025, then jumped by 38.45% to $148.8 million in 2026.
• The last three Payables figures came in at $148.8 million (Q1 2026), $107.5 million (Q4 2025), and $112.3 million (Q3 2025), per Business Quant data.